Nearly $10m between the two expense categories below for 2015 financial and still at pre clinical trials stage and awaiting toxicology programs to be completed
It is paramount that they use the $44m remaining cash wisely as in reality this will barely touch the surface in the next 12-24 months as they endeavour to hopefully bring one or two or three drugs through the various phases with success..
imo, The potential $33m from the December options is crucial going forward as if they lapse trying to complete another CR will be very difficult let alone anywhere near 30c
The question is what can increase the share price well over 100% from here in such a short period of time to allow the options to be in the money
Column 1
Column 2
0
Expenses
Research and development expense (5,935,357)
General and administrative expense (3,843,785)
DYOR
NRT Price at posting:
15.5¢ Sentiment: Hold Disclosure: Held
